hERG Channels: From Antitargets to Novel Targets for Cancer Therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27903676.
- Also identified by DOI 10.1158/1078-0432.CCR-16-2322.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K<sup>+</sup> channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans. Clin Cancer Res; 23(1); 3-5. ©2016 AACRSee related article by Pointer et al., p. 73.
Medical subject headings
- Antineoplastic Agents
- Biomarkers, Tumor
- Ether-A-Go-Go Potassium Channels
- Potassium Channel Blockers